Mission Statement, Vision, & Core Values (2026) of Cathay Biotech Inc.

Cathay Biotech Inc. (688065.SS), founded in 2000 and headquartered in Zhangjiang Hi‑Tech Park, Shanghai with production facilities in Jinxiang and Wusu and a third site under construction in Taiyuan, is driving the polyamide value chain through bio-manufactured long-chain diacids and bio-based pentamethylene diamine used across textiles, pharmaceuticals, perfumes, automotive and electronics markets; recognized in 2018 as a national champion for its long-chain diacid products, the company backs its mission to accelerate synthetic biology and bio-manufacturing with heavy R&D investment-approximately $87 million in 2024, about 10% of revenue-while pursuing a vision to lead global all‑natural performance materials and a core-values agenda that delivered a 12% reduction in greenhouse gas emissions in 2024, sourced 100% of raw materials from sustainable suppliers, forged five new university partnerships, maintained 100% regulatory compliance, achieved 95% employee participation in ethics training, and recorded a 92% customer satisfaction rating from over 1,500 clients-read on to see how these measurable commitments shape Cathay Biotech's strategy, capacity expansion, and industry leadership.

Cathay Biotech Inc. (688065.SS) - Intro

• Founded: 2000
• Stock code: 688065.SS (Shanghai STAR Market)
• Headquarters & R&D: Zhangjiang Hi‑Tech Park, Shanghai
• Production sites: Jinxiang and Wusu (China); third site under construction in Taiyuan
• Core product focus: bio-manufactured long‑chain diacids and bio‑based pentamethylene diamine (monomers for bio‑based polyamides)
• Recognition: products rated as individual champion products by the Ministry of Industry and Information Technology and China Federation of Industrial Economics (2018)

• Technology platform: synthetic biology, metabolic engineering and scale‑up bio‑manufacturing processes aimed at replacing petrochemical monomers in polyamide supply chains.
• Market position: recognized leader in bio‑manufactured long‑chain diacids with global supply relationships across textile, automotive and specialty chemical customers.
• Sustainability focus: reducing carbon intensity by substituting fossil feedstocks with bio‑based fermentation routes and planning capacity expansion to meet rising demand for greener polyamide inputs.

• Mission: Advance sustainable, scalable bio‑manufacturing to supply high‑performance monomers that enable a lower‑carbon polyamide industry worldwide.
• Vision: Be the global leader in bio‑based monomers for high‑value polymer applications, driven by industrialized synthetic biology and customer‑centric product development.
• Core values:
  • Innovation - continuous R&D investment in strain engineering and process intensification.
  • Quality & reliability - industrial production standards to meet textile, pharmaceutical and automotive specifications.
  • Sustainability - lifecycle carbon reduction and resource efficiency across feedstock-to-product pathways.
  • Partnership - close collaboration with downstream polymer makers, brands and chemical distributors to scale adoption.

• Capacity expansion: completion and ramp of the Taiyuan site to increase aggregate annual production of bio‑diacids and bio‑diamines.
• Commercial scale‑up: further scale of fermentation, downstream purification and supply reliability to secure long‑term contracts with polymer producers and brands.
• R&D milestones: strain yield improvements, reduced downstream processing costs, and new monomer product introductions to broaden addressable markets.
• Market adoption metrics: contract volumes (tpa), average selling price per tonne, and % revenue from long‑term offtake agreements.

Cathay Biotech Inc. (688065.SS) - Overview

• Mission: Promote innovation of bio-based products and technologies based on four core technologies, providing a positive force in synthetic biology and bio-manufacturing and leading sustainable technological and industrial development.
• Vision: To be a global pioneer in industrial synthetic biology and bio-manufacturing, delivering scalable, eco-efficient bio-based materials that reduce environmental impact and enable circular-resource models.
• Core values: scientific rigor, sustainability, innovation, collaboration, and long-term stewardship of technologies and ecosystems.

• Strategic focus areas:
  • Four core technology platforms (strain engineering, fermentation process development, downstream processing, and bioproduct formulation).
  • Scaling pilot-to-commercial production with modular facilities and partnerships.
  • Investing in platform R&D to shorten development cycles and improve yields.
• Sustainability priorities:
  • Resource efficiency (water, energy) in bio-manufacturing operations.
  • Lifecycle reduction of carbon and waste through bio-based replacements.

• Maintaining high R&D intensity to commercialize new bio-based products and optimize yields.
• Expanding production capacity in line with validated product-market fit and partnerships.
• Aligning product development with sustainability metrics (e.g., lifecycle emissions, feedstock efficiency).
• Engaging industry and academic collaborators to accelerate technology transfer and application breadth.

Cathay Biotech Inc. (688065.SS) - Mission Statement

• Prioritize R&D to convert renewable feedstocks into high‑performance polymers, additives, and specialty ingredients.
• Operate manufacturing with low environmental footprint and measurable life‑cycle improvements versus fossil alternatives.
• Deliver commercially viable products that meet or exceed performance benchmarks for durability, safety, and cost‑effectiveness.
• Engage supply chain partners and customers to enable circularity and end‑of‑life solutions for bio‑materials.

• Align product roadmaps with industry sustainability targets (e.g., carbon reduction, reduced microplastic leakage).
• Target applications where performance parity or superiority can be demonstrated-automotive, consumer packaging, specialty coatings, and textiles.
• Scale proven technologies from lab to commercial output while maintaining traceability and certification (e.g., compostability, renewable content verification).

• R&D allocation: sustained multi‑year investment to drive formulation, processing, and scale‑up; target R&D intensity in line with specialty peers (mid‑single to low‑double digit % of revenue).
• Scale‑up: phased capital expenditure to move from pilot capacity (tons/month) to commercial lines (hundreds to thousands of tons/year), matched to end‑market demand.
• Quality & certifications: pursue third‑party verification for renewable content, biodegradability/compostability, and ISO quality systems to enable global sales.
• Sales & partnerships: secure offtake and co‑development agreements with consumer goods manufacturers and industrial processors to de‑risk scale‑up.

• Regulatory tailwinds in EU, China, and North America favor bio‑based content, extended producer responsibility, and reduced single‑use plastics-creating preferential procurement and compliance incentives.
• Corporate ESG commitments among large consumer brands are driving supplier shifts; procurement tenders increasingly require lifecycle data and certified renewable content.
• Public markets and investors are increasingly valuing measurable decarbonization pathways and circularity-supporting equity and project finance for scale‑up.

• Technology platform diversification: combining fermentation‑derived intermediates, plant‑based polymers, and bio‑functional additives to address multiple performance vectors.
• Process optimization to lower unit costs and reduce energy and water intensity-improving competitiveness versus fossil incumbents.
• Strategic partnerships: licensing, joint ventures, and OEM collaborations to accelerate volume adoption and geographic reach.
• Supply chain resilience: secure sustainable feedstocks with traceability, and implement logistics strategies to minimize emissions and cost volatility.

Cathay Biotech Inc. (688065.SS) - Vision Statement

• Innovation: Dedicate resources to breakthrough R&D-$87 million invested in 2024, representing ~10% of total revenue (implying ~ $870 million revenue in 2024).
• Sustainability: Commit to carbon and resource stewardship-12% reduction in greenhouse gas emissions in 2024 and 100% of raw materials sourced from sustainable suppliers.
• Collaboration: Scale knowledge networks-five new strategic university partnerships formed in 2024 to accelerate translational research.
• Integrity: Uphold governance and compliance-100% regulatory compliance in 2024 and 95% employee participation in a company-wide ethics training program.
• Customer-centricity: Deliver measurable client value-92% customer satisfaction in 2024 from surveys of over 1,500 clients across industries.

• Invest strategically in pipeline programs and platform technologies to sustain a ~10% revenue reinvestment in R&D annually.
• Embed sustainability metrics into procurement and manufacturing-ensure continued 100% sustainable sourcing and incremental GHG reductions beyond the 12% achieved in 2024.
• Expand collaborative networks with academia and industry partners to accelerate clinical translation and share infrastructure costs.
• Maintain uncompromising compliance and ethics culture through ongoing audits and recurring training to preserve the 100% compliance record.
• Drive customer-centric product development informed by large-scale client feedback loops-leverage the 92% satisfaction benchmark to prioritize feature adoption and service improvements.